Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Center for Biologics Evaluation and Research (CBER)

Center for Biologics Evaluation and Research (CBER)

                        CBER Offices & Divisions
          CBER Vision & Mission
          CBER Reports
          CBER Ombudsman
          CBER Product Jurisdiction
          Jobs at the Center for Biologics Evaluation and Research (CBER) Home
          About FDA
          FDA Organization
          Center for Biologics Evaluation and Research (CBER)
          CBER Product JurisdictionCenter for Biologics Evaluation and Research (CBER) CBER Product Jurisdiction
  
  	
    Share
    Post
    Linkedin

    Email
    PrintCBER regulates a variety of different product types including biologics such as allergenics, blood and blood products, cellular & gene therapies, tissue and tissue-based products, vaccines and xenotransplantation products. We also regulate some devices including selected in vitro diagnostics and devices that manufacture a biologic at the point of care, as well as a small number of drug products related to blood banking or cellular therapies. These products are distributed among three product review offices within CBER: **Office of Vaccines Research and Review (OVRR), Office of Tissues and Advanced Therapies (OTAT) and the Office of Blood Research and Review (OBRR)**.  CBER’s allergenic products, infectious disease vaccines and live biotherapeutic (probiotic) therapies are regulated by OVRR. OTAT regulates cell, tissue and gene therapies as well as therapeutic vaccines for various disease indications. OBRR regulates blood and blood products, including plasma derivatives and their recombinant analogues. OBRR is also responsible for the regulation of blood donor screening assays and retroviral diagnostic tests.

CBER’s product jurisdiction officer provides a resource for sponsors and research investigators who have questions about how their product is classified (e.g., a biologic, drug, device, combination, 361 HCT/P or other), who regulates it (which center or which office within CBER), or which regulatory path/requirements apply. Classification and jurisdiction determinations can be made informally or formally. Informal assignment questions can be submitted directly to CBER’s jurisdiction officer using the e-mail or phone contact information provided below.

**CBER Product Jurisdiction Officer**
Food and Drug Administration
Center for Biologics Evaluation and Research
10903 New Hampshire Ave
WO71-7240
Silver Spring, MD 20993-0002

Phone: 240-402-7912
Email: CBERProductJurisdiction@fda.hhs.gov

Formal assignment requests require the submission of a Request for Designation Document (RFD) to FDA’s Office of Combination Products.

**CBER 513(g)**

CBER’s 513(g) coordinator oversees the review and response to Section 513(g) “Requests for Information under the Federal Food, Drug, and Cosmetic Act (FD&C Act),” that have been submitted to CBER.  These requests are regarding the class in which a device has been classified or the requirements applicable to a device under the FD&C Act.

For information on 513(g) user fees, please refer to the following guidance document:http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm209852.htm

Please submit **CBER 513(g)** submissions to :

**CBER 513(g) Coordinator**
Food and Drug Administration
Center for Biologics Evaluation and Research
10903 New Hampshire Ave
WO71-G112
Silver Spring, MD 20993-0002

                                                                                  Content current as of:
      03/26/2018Center for Biologics Evaluation and Research (CBER)

          
                        CBER Offices & Divisions
          CBER Vision & Mission
          CBER Reports
          CBER Ombudsman
          CBER Product Jurisdiction
          Jobs at CBER
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop